Medpace Holdings, Inc. (NASDAQ:MEDP – Get Free Report) CEO August Troendle sold 3,728 shares of the stock in a transaction on Monday, July 27th. The shares were sold at an average price of $600.85, for a total value of $2,239,968.80. Following the transaction, the chief executive officer directly owned 642,456 shares in the company, valued at $386,019,687.60. The trade was a 0.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Medpace Price Performance
MEDP stock opened at $577.11 on Friday. Medpace Holdings, Inc. has a 1 year low of $373.00 and a 1 year high of $677.90. The company has a market cap of $16.11 billion, a P/E ratio of 33.83, a price-to-earnings-growth ratio of 2.58 and a beta of 1.15. The stock’s fifty day moving average price is $507.61 and its 200-day moving average price is $493.77.
Medpace (NASDAQ:MEDP – Get Free Report) last posted its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The company had revenue of $707.33 million during the quarter, compared to analysts’ expectations of $689.51 million. During the same quarter in the prior year, the business earned $3.10 earnings per share. Medpace’s revenue for the quarter was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, analysts expect that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.
Institutional Trading of Medpace
Wall Street Analysts Forecast Growth
Several equities research analysts have recently commented on the stock. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Medpace in a research report on Thursday, July 2nd. Leerink Partners set a $620.00 target price on shares of Medpace in a research report on Thursday, July 23rd. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $535.00 target price on shares of Medpace in a research report on Thursday, July 23rd. TD Cowen increased their price target on shares of Medpace from $419.00 to $492.00 and gave the stock a “hold” rating in a research report on Friday, July 24th. Finally, Truist Financial increased their price target on shares of Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a research report on Friday, July 24th. Two investment analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the stock. Based on data from MarketBeat.com, Medpace has an average rating of “Hold” and an average price target of $584.18.
Read Our Latest Stock Analysis on Medpace
About Medpace
Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.
Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.
Read More
- Five stocks we like better than Medpace
- Chevron’s Strong Quarter Shows Why It Still Leads the Energy Sector
- Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case
- Apple’s Record Quarter Could Not Outrun Its Guidance Problem
- McKesson’s Compounding Keeps Adding Up
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.
